東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Combined Cell and Gene Therapy towar...

Petrou, Sabiha Hacibekiroglu.

Linked to FindBook

Google Book

Amazon

博客來

Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy./
Author:	Petrou, Sabiha Hacibekiroglu.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	205 p.
Notes:	Source: Dissertations Abstracts International, Volume: 80-01, Section: B.
Contained By:	Dissertations Abstracts International80-01B.
Subject:	Biology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10688594
ISBN:	9780438186743

Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy.
Petrou, Sabiha Hacibekiroglu.

Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 205 p.

Source: Dissertations Abstracts International, Volume: 80-01, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2018.

This item must not be sold to any third party vendors.

Abnormal and leaky blood vessel growth (neovascularization, NV), caused by an up-regulation of VEGF, is the common cause for vascular leakage, vessel dilatation, tortuosity, haemorrhage, cell death and ultimately blindness in age-related macular degeneration and diabetic retinopathy. Current anti-VEGF treatments (e.g. Avastin) can improve visual function but only temporarily and therefore patients require monthly eye injections. In addition, the anti-VEGF therapies cause side effects such as stroke, gastrointestinal perforations and bleeding. To address these problems, we have generated a novel bi-functional VEGF trap (VEGF Sticky-trap) that is able to trap VEGF as well as bind ("stick") to the extracellular matrix (ECM). This consequently allows inhibition of neovascularization only at the site of administration without causing systemic side effects as we have demonstrated in a retinopathy mouse model (OIR). To avoid the invasiveness of current therapies we have generated retinal pigment epithelium cells that express VEGF Sticky-trap in an inducible manner. We have shown that VEGF Sticky-trap expressed by these cells in-vitro is able to bind to ECM and trap soluble VEGF only upon doxycycline induction. In addition, we have demonstrated that these cells incorporate into the subretinal space long-term (up to 10 month), express VEGF Sticky-trap that a) remains bound to eye ECM and b) inhibits laser-induced chorodial NV. Here we have shown that the combination of cell and novel anti-VEGF gene therapy can inhibit neovascularization in a controlled and long-term manner; potentially improve vision, while avoiding the risk of side effects.

ISBN: 9780438186743Subjects--Topical Terms:

522710
Biology.

Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy.
LDR:02806nmm a2200337 4500 001 2210270
005 20191121124156.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438186743
035 $a (MiAaPQ)AAI10688594
035 $a (MiAaPQ)toronto:17018
035 $a AAI10688594
040 $a MiAaPQ $c MiAaPQ
100 1 $a Petrou, Sabiha Hacibekiroglu. $3 3437414
245 1 0 $a Combined Cell and Gene Therapy towards the Treatment of Age-related Macular Degeneration and Diabetic Retinopathy.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 205 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-01, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Nagy, Andras.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2018.
506 $a This item must not be sold to any third party vendors.
520 $a Abnormal and leaky blood vessel growth (neovascularization, NV), caused by an up-regulation of VEGF, is the common cause for vascular leakage, vessel dilatation, tortuosity, haemorrhage, cell death and ultimately blindness in age-related macular degeneration and diabetic retinopathy. Current anti-VEGF treatments (e.g. Avastin) can improve visual function but only temporarily and therefore patients require monthly eye injections. In addition, the anti-VEGF therapies cause side effects such as stroke, gastrointestinal perforations and bleeding. To address these problems, we have generated a novel bi-functional VEGF trap (VEGF Sticky-trap) that is able to trap VEGF as well as bind ("stick") to the extracellular matrix (ECM). This consequently allows inhibition of neovascularization only at the site of administration without causing systemic side effects as we have demonstrated in a retinopathy mouse model (OIR). To avoid the invasiveness of current therapies we have generated retinal pigment epithelium cells that express VEGF Sticky-trap in an inducible manner. We have shown that VEGF Sticky-trap expressed by these cells in-vitro is able to bind to ECM and trap soluble VEGF only upon doxycycline induction. In addition, we have demonstrated that these cells incorporate into the subretinal space long-term (up to 10 month), express VEGF Sticky-trap that a) remains bound to eye ECM and b) inhibits laser-induced chorodial NV. Here we have shown that the combination of cell and novel anti-VEGF gene therapy can inhibit neovascularization in a controlled and long-term manner; potentially improve vision, while avoiding the risk of side effects.
590 $a School code: 0779.
650 4 $a Biology. $3 522710
650 4 $a Cellular biology. $3 3172791
650 4 $a Developmental biology. $3 592588
690 $a 0306
690 $a 0379
690 $a 0758
710 2 $a University of Toronto (Canada). $b Medical Science. $3 3182952
773 0 $t Dissertations Abstracts International $g 80-01B.
790 $a 0779
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10688594